Jenner Biotherapies Receives Australian Patent Covering Prostate Cancer Vaccine.SAN RAMON, Calif.--(BW HealthWire)--June 24, 1998--Jenner Biotherapies today announced that it has been issued Australian patent #76312/94, "Prostatic Cancer Vaccine." The patent covers the use of PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce. , PSMA PSMA Public Sector Mapping Agencies (Australia) PSMA Prostate-Specific Membrane Antigen PSMA Power Sources Manufacturers Association PSMA Pakistan Sugar Mills Association PSMA Professional Services Management Association , and PAP, inclusive of derivatives, peptides, anti-idiotypic antibodies, viral vectors and naked DNA. "This is an exceedingly broad patent relative to the use of these antigens in cancer patients and places Jenner in a premier position in vaccine therapy vaccine therapy A therapeutic strategy to boost the immune response against a particular pathogen to such degree that the vaccine alone is enough to treat the Pt for prostate cancer," said Anthony E. Maida, Chief Executive Officer. "We expect similar coverage in Europe and the United States." The Company is engaged in U.S. clinical trials of OncoVax-P(tm), vaccine for therapy of prostate cancer using a liposomal formulation of recombinant prostate specific antigen PSA (Prostate specific antigen) A tumor marker associated with prostate cancer. Mentioned in: Tumor Markers (PSA) and AdjuVax-100a(tm), Jenner's proprietary vaccine adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. for the treatment of prostate cancer. Jenner Biotherapies of San Ramon, Calif., is involved in the development and clinical evaluation of immunotherapies for patients with cancer. The focus is on treating patients who have a minimal tumor burden in an effort to slow disease progression and improve survival and quality of life in patients with cancer. The Company has three product platforms for cancer immunotherapy; one involving the use of recombinant vaccines, a second involving macrophage macrophage /mac·ro·phage/ (mak´ro-faj) any of the large, mononuclear, highly phagocytic cells derived from monocytes that occur in the walls of blood vessels (adventitial cells) and in loose connective tissue (histiocytes, phagocytic activators, and a third involving a vaccine adjuvant. Jenner Biotherapies is located at 2010 Crow Canyon Place, Suite 100, San Ramon, Calif., 94583-1344; phone 510/824-3150; FAX 510/824-3151; email amaida@jennerbio.com; WEB site http://www.jennerbio.com.
CONTACT: Jenner Biotherapies
Anthony E. Maida, III, MA, MBA
Chief Executive Officer
510/824-3150
or
Lynn E. Spitler, MD
Senior Vice President/
Chief Scientific Officer
415/435-9861
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion